Next Article in Journal
The mito-QC Reporter for Quantitative Mitophagy Assessment in Primary Retinal Ganglion Cells and Experimental Glaucoma Models
Next Article in Special Issue
Identification of Inhibitors to Trypanosoma cruzi Sirtuins Based on Compounds Developed to Human Enzymes
Previous Article in Journal
Deciphering the Role of Multiple Thioredoxin Fold Proteins of Leptospirillum sp. in Oxidative Stress Tolerance
Previous Article in Special Issue
High Cell Selectivity and Bactericidal Mechanism of Symmetric Peptides Centered on d-Pro–Gly Pairs
 
 
Review

Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens

by 1,2,3 and 1,2,3,*
1
Biocomputation and Complex Systems Physics Institute (BIFI)-Joint Units: BIFI-IQFR (CSIC) and GBsC-CSIC, University of Zaragoza, 50018 Zaragoza, Spain
2
Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, University of Zaragoza, 37009 Zaragoza, Spain
3
Aragon Health Research Institute (IIS Aragón), 50009 Zaragoza, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(5), 1881; https://doi.org/10.3390/ijms21051881
Received: 14 February 2020 / Revised: 4 March 2020 / Accepted: 6 March 2020 / Published: 10 March 2020
(This article belongs to the Special Issue Biochemistry, Molecular Biology and Druggability of Proteins)
Flavodoxins are small soluble electron transfer proteins widely present in bacteria and absent in vertebrates. Flavodoxins participate in different metabolic pathways and, in some bacteria, they have been shown to be essential proteins representing promising therapeutic targets to fight bacterial infections. Using purified flavodoxin and chemical libraries, leads can be identified that block flavodoxin function and act as bactericidal molecules, as it has been demonstrated for Helicobacter pylori (Hp), the most prevalent human gastric pathogen. Increasing antimicrobial resistance by this bacterium has led current therapies to lose effectiveness, so alternative treatments are urgently required. Here, we summarize, with a focus on flavodoxin, opportunities for pharmacological intervention offered by the potential protein targets described for this bacterium and provide information on other gastrointestinal pathogens and also on bacteria from the gut microbiota that contain flavodoxin. The process of discovery and development of novel antimicrobials specific for Hp flavodoxin that is being carried out in our group is explained, as it can be extrapolated to the discovery of inhibitors specific for other gastric pathogens. The high specificity for Hp of the antimicrobials developed may be of help to reduce damage to the gut microbiota and to slow down the development of resistant Hp mutants. View Full-Text
Keywords: flavodoxin; drug discovery; therapeutic target; Helicobacter pylori (Hp); antimicrobial resistance; gastric pathogens; gastric microbiota flavodoxin; drug discovery; therapeutic target; Helicobacter pylori (Hp); antimicrobial resistance; gastric pathogens; gastric microbiota
Show Figures

Figure 1

MDPI and ACS Style

Salillas, S.; Sancho, J. Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens. Int. J. Mol. Sci. 2020, 21, 1881. https://doi.org/10.3390/ijms21051881

AMA Style

Salillas S, Sancho J. Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens. International Journal of Molecular Sciences. 2020; 21(5):1881. https://doi.org/10.3390/ijms21051881

Chicago/Turabian Style

Salillas, Sandra, and Javier Sancho. 2020. "Flavodoxins as Novel Therapeutic Targets against Helicobacter pylori and Other Gastric Pathogens" International Journal of Molecular Sciences 21, no. 5: 1881. https://doi.org/10.3390/ijms21051881

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop